Veru reports fiscal 2024 first quarter financial highlights

—company receives fda ind clearance for the development of enobosarm in combination with glp-1 drugs for potentially higher quality weight loss than has been shown with glp-1 drug alone—

VERU Ratings Summary

VERU Quant Ranking